FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572663346> ?p ?o ?g. }

• W2572663346 abstract "Abstract Abstract 355FN2 We have previously shown that adoptive transfer of haploidentical natural killer (NK) cells can induce remissions in patients with refractory or relapsed acute myeloid leukemia (AML). We hypothesize that in vivo expansion of functional NK cells is required for therapeutic efficacy. To achieve the adequate host immune suppression required for expansion we added total body irradiation (TBI) to our lymphodepleting chemotherapy regimen, giving patients fludarabine (Flu) 25 mg/m2 × 5 days, cyclophosphamide (Cy) 60 mg/kg × 2 days, and 400 cGy of TBI. The NK cell product, a CD3- and CD19-depleted lymphapheresis from a haploidentical related donor, was incubated overnight in 1000 U/ml IL-2 and infused followed by 6 doses of alternate day subcutaneous IL-2 (10 million units) to promote in vivo expansion. Because of the increased myelosuppression following the TBI, a CD34-selected filgrastim-mobilized peripheral blood graft from the same donor (target dose >3 × 106 CD34 cells/kg) was given for hematopoietic rescue. Successful in vivo NK cell expansion was prospectively defined as >100 donor-derived NK cells/ml at 14 days after adoptive transfer (by analysis of STR chimerism, % NK and the clinical absolute lymphocyte count). In the 38 evaluable patients, robust in vivo expansion was induced in 50% (absolute donor NK count of 666 ± 134 cells/μL blood), a rate considerably higher than the 10% we observed in a cohort receiving Cy/Flu alone without TBI. Successful NK cell expansion correlated with leukemia clearance (<1% marrow blasts 14 days after NK cell infusion) and remission (leukemia free with donor neutrophil engraftment at day +30; 42 days after NK infusion). Of the 19 patients who achieved NK cell expansion, 89% cleared their leukemia compared to 42% of the non-expanders (p=0.002); and 84% achieved remission vs. 10% of non-expanders (p <.0001). The robust in vivo expansion of adoptively transferred NK cells gave us the unique opportunity to study their function. We studied blood collected from patients 14 days after NK cell infusion and compared it to paired donor samples obtained at steady state from the apheresis products prior to IL-2 stimulation. Using multi-color flow cytometry, we measured CD107a expression (a surrogate marker for NK cell cytotoxicity) on NK cells which we could subset by expression of single inhibitory killer cell immunoglobulin-like receptors (KIR) (CD158a, CD158b and CD158e) or NKG2A. We defined NK subsets as self-KIR+ or non-self KIR+ based on the cognate HLA ligands (C2, C1, Bw4) present in the donor or recipient. The bulk population of in vivo expanded donor NK cells exhibited hyperfunction with 62.4±4.4% degranulation in response to class I negative K562 targets compared to 36.6±3.0% in the donor product samples (N=15; p=0.0043). As expected, the most potent NK cells in the unstimulated donor product were the self-KIR+ subset, which expressed 39.5±3.0% CD107a after incubation with K562 (N=23) compared to either the non-self KIR+subset (13.1±4.0%, N=6; p=0.0001), or the uneducated KIR−/NKG2A− subset (12.4±5.8%, N=10; p<0.0001). Remarkably, all 3 subsets exhibited even greater degranulation activity after 14 days of in vivo expansion where they were exposed to homeostatic factors and the IL-2 administered to the patient. While all subsets expressed more CD107a, the rules of education were maintained. The subset expressing self-KIR that recognized donor HLA ligands degranulated significantly better than the non-self KIR+ subset (53.5±14.1% vs. 34.3±13.6%, p<0.01). Interestingly, the in vivo expanded NK cells with KIR recognizing cognate ligands unique to the recipient also functioned better (53.1±14.3% [recipient self KIR+] vs. 32.4±12.0% [non-self KIR+], N=25 and N=6; p<0.0045), showing that the education status of adult NK cells is dynamic, not fixed. Importantly, the KIR−/NKG2A− subset functioned better after in vivo expansion (39.5±115.3%, N=12), demonstrating that adoptively transferred NK cells can acquire function by two separate mechanisms: 1) acquisition of function through NK cell education; and 2) acquisition of function by homeostatic expansion and cytokine activation. These data suggest that while hyperfunctioning NK cells that expand in vivo after adoptive transfer partially overcome self tolerance, which may augment their anti-leukemic effects, they still follow the rules of NK cell education where self KIR+ cells kill better than non-self KIR+ cells. Disclosures: No relevant conflicts of interest to declare." @default.
• W2572663346 created "2017-01-26" @default.
• W2572663346 creator A5008133433 @default.
• W2572663346 creator A5009609420 @default.
• W2572663346 creator A5009794386 @default.
• W2572663346 creator A5027151969 @default.
• W2572663346 creator A5052896867 @default.
• W2572663346 creator A5058268746 @default.
• W2572663346 creator A5061426484 @default.
• W2572663346 creator A5070132319 @default.
• W2572663346 creator A5084167089 @default.
• W2572663346 date "2011-11-18" @default.
• W2572663346 modified "2023-09-27" @default.
• W2572663346 title "Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia" @default.
• W2572663346 doi "https://doi.org/10.1182/blood.v118.21.355.355" @default.
• W2572663346 hasPublicationYear "2011" @default.
• W2572663346 type Work @default.
• W2572663346 sameAs 2572663346 @default.
• W2572663346 citedByCount "5" @default.
• W2572663346 countsByYear W25726633462012 @default.
• W2572663346 countsByYear W25726633462014 @default.
• W2572663346 countsByYear W25726633462016 @default.
• W2572663346 countsByYear W25726633462017 @default.
• W2572663346 crossrefType "journal-article" @default.
• W2572663346 hasAuthorship W2572663346A5008133433 @default.
• W2572663346 hasAuthorship W2572663346A5009609420 @default.
• W2572663346 hasAuthorship W2572663346A5009794386 @default.
• W2572663346 hasAuthorship W2572663346A5027151969 @default.
• W2572663346 hasAuthorship W2572663346A5052896867 @default.
• W2572663346 hasAuthorship W2572663346A5058268746 @default.
• W2572663346 hasAuthorship W2572663346A5061426484 @default.
• W2572663346 hasAuthorship W2572663346A5070132319 @default.
• W2572663346 hasAuthorship W2572663346A5084167089 @default.
• W2572663346 hasConcept C126322002 @default.
• W2572663346 hasConcept C150903083 @default.
• W2572663346 hasConcept C154317977 @default.
• W2572663346 hasConcept C202751555 @default.
• W2572663346 hasConcept C203014093 @default.
• W2572663346 hasConcept C207001950 @default.
• W2572663346 hasConcept C2776090121 @default.
• W2572663346 hasConcept C2776694085 @default.
• W2572663346 hasConcept C2776755627 @default.
• W2572663346 hasConcept C2776863199 @default.
• W2572663346 hasConcept C2777408962 @default.
• W2572663346 hasConcept C2778102761 @default.
• W2572663346 hasConcept C2778461978 @default.
• W2572663346 hasConcept C2778729363 @default.
• W2572663346 hasConcept C2778880498 @default.
• W2572663346 hasConcept C2779263901 @default.
• W2572663346 hasConcept C2911091166 @default.
• W2572663346 hasConcept C55493867 @default.
• W2572663346 hasConcept C71924100 @default.
• W2572663346 hasConcept C86803240 @default.
• W2572663346 hasConcept C8891405 @default.
• W2572663346 hasConcept C90375314 @default.
• W2572663346 hasConceptScore W2572663346C126322002 @default.
• W2572663346 hasConceptScore W2572663346C150903083 @default.
• W2572663346 hasConceptScore W2572663346C154317977 @default.
• W2572663346 hasConceptScore W2572663346C202751555 @default.
• W2572663346 hasConceptScore W2572663346C203014093 @default.
• W2572663346 hasConceptScore W2572663346C207001950 @default.
• W2572663346 hasConceptScore W2572663346C2776090121 @default.
• W2572663346 hasConceptScore W2572663346C2776694085 @default.
• W2572663346 hasConceptScore W2572663346C2776755627 @default.
• W2572663346 hasConceptScore W2572663346C2776863199 @default.
• W2572663346 hasConceptScore W2572663346C2777408962 @default.
• W2572663346 hasConceptScore W2572663346C2778102761 @default.
• W2572663346 hasConceptScore W2572663346C2778461978 @default.
• W2572663346 hasConceptScore W2572663346C2778729363 @default.
• W2572663346 hasConceptScore W2572663346C2778880498 @default.
• W2572663346 hasConceptScore W2572663346C2779263901 @default.
• W2572663346 hasConceptScore W2572663346C2911091166 @default.
• W2572663346 hasConceptScore W2572663346C55493867 @default.
• W2572663346 hasConceptScore W2572663346C71924100 @default.
• W2572663346 hasConceptScore W2572663346C86803240 @default.
• W2572663346 hasConceptScore W2572663346C8891405 @default.
• W2572663346 hasConceptScore W2572663346C90375314 @default.
• W2572663346 hasLocation W25726633461 @default.
• W2572663346 hasOpenAccess W2572663346 @default.
• W2572663346 hasPrimaryLocation W25726633461 @default.
• W2572663346 hasRelatedWork W2030322847 @default.
• W2572663346 hasRelatedWork W2049024742 @default.
• W2572663346 hasRelatedWork W2052110513 @default.
• W2572663346 hasRelatedWork W2112535311 @default.
• W2572663346 hasRelatedWork W2211834287 @default.
• W2572663346 hasRelatedWork W2361664010 @default.
• W2572663346 hasRelatedWork W2526159855 @default.
• W2572663346 hasRelatedWork W2531653003 @default.
• W2572663346 hasRelatedWork W2549256360 @default.
• W2572663346 hasRelatedWork W2561021282 @default.
• W2572663346 hasRelatedWork W2565347146 @default.
• W2572663346 hasRelatedWork W2778306931 @default.
• W2572663346 hasRelatedWork W283869903 @default.
• W2572663346 hasRelatedWork W2969758385 @default.
• W2572663346 hasRelatedWork W2979667348 @default.
• W2572663346 hasRelatedWork W2993316527 @default.
• W2572663346 hasRelatedWork W3028161503 @default.
• W2572663346 hasRelatedWork W3114208348 @default.
• W2572663346 hasRelatedWork W3165594307 @default.
• W2572663346 hasRelatedWork W3196700379 @default.

• next